Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01790438 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 641
- Enrollment target
NCT01790438 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 641 participants.
The verdict
NCT01790438, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 641 participants
- Enrollment target
Study Summary
The purpose of this study is to compare LY2605541 and human insulin isophane suspension (NPH) using the following measures for participants treated for up to 26 weeks: * Change in participants' overall blood sugar control * The rate of night time low blood sugar episodes * The number of participants that reach blood sugar targets without low night time blood sugar episodes * The total number of low blood sugar episodes reported
Interventions
- DRUG LY2605541
- DRUG Human Insulin NPH
- DRUG Oral Antihyperglycemic Medications (OAM)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 641 participants |
| Start Date | 2013-03 |
| Est. Completion | 2014-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01790438
The ClinicalTrials.gov registry entry for NCT01790438 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 641 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which LY2605541 is the first listed.
NCT01790438 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01790438 about?
NCT01790438 is a clinical study titled "A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes". The purpose of this study is to compare LY2605541 and human insulin isophane suspension (NPH) using the following measures for participants treated for up to 26 weeks: * Change in participants' overall blood sugar control * The rate of night time low blood sugar episodes * The number of participant...
What is the current status of trial NCT01790438?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 641 participants. The study started on 2013-03. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01790438?
The interventions under investigation include: LY2605541 (DRUG), Human Insulin NPH (DRUG), Oral Antihyperglycemic Medications (OAM) (DRUG).
Who is sponsoring clinical trial NCT01790438?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.